Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phasaae 1 CLOVER study

Approximately 80 –85% of all lung cancer cases are non-small-cell lung cancer (NSCLC), with around 20–35% of patients presenting with stage III disease [1–4]. In the placebo-controlled, phase 3 PACIFIC trial (NCT02125461) of patients with unresectable, stage III NSCLC whose disease had not progressed following concurrent chemoradiotherapy (cCRT), consolidation therapy with the programmed cell death ligand-1 (PD-L1) inhibitor durvalumab significantly improved overall survival (OS) and progression-free survival (PFS), with a manageable safety profile [5,6].

Source: Lung Cancer - March 6, 2024 Category: Cancer & Oncology Authors: Dong-Wan Kim, Byoung Chul Cho, Krishna Pachipala, Sang-We Kim, Chih-Liang Wang, Gee-Chen Chang, Myung-Ju Ahn, Rosa Alvarez, Chao-Hua Chiu, Jos é Trigo, Anna Estival, Sana D. Karam, Cathy O'Brien, Hema Gowda, Haiyi Jiang, Julie E. Bauman Source Type: research